Endocrine Abstracts

Aggressive pituitary tumours, characterized by tumor recurrence and continued progression despite repeated treatments and pituitary carcinomas respond poorly to conventional therapies. The first reports describing the successful use of temozolomide (TMZ), an orally administered alkylating agent used to treat malignant gliomas, in the management of pituitary carcinomas were published in 2006. Following these single case reports small series of patients have detailed the success...

Pituitary endocrine tumours are currently classified by histological, immunocytochemical and numerous ultrastructural characteristics but without prognostic clinical correlations. We investigated the prognostic value of a new clinicopathological classification with grades based on invasion and proliferation, the components of tumour behaviour.This retrospective multicentric case–control study comprised 410 patients who had surgery for a pituitary tu...

Objective: To describe the Carney Complex (CNC) manifestations presented by patients harboring the PRKAR1A mutation c.709(-7-2)del (one of the three hotspots) in a large cohort of patients.Methods: Multicenter retrospective study. Age at the diagnosis or at the screening of the different CNC manifestations is described by mean ± standard deviation.Results: Forty patients [12 index cases, 27 females, 46±15 years o...

Background: In a phase 3b, open-label study (NCT02354508) assessing efficacy and safety of long-acting pasireotide in patients with uncontrolled acromegaly after ≥3 months of treatment with first-generation SSAs, 18/123 (15%) patients achieved the primary endpoint of mean growth hormone (mGH) <1.0 μg/l and insulin-like growth factor-1 (IGF-1) <ULN (upper limit of normal) at week 36. Here, we present the results from the extension phase of this study.<p c...

Introduction: Dopamine agonists (DA), reference treatment for microprolactinomas, rarely allow long term remission. The performance of endoscopic pituitary surgery should be examined as first-line treatment.Objective: To evaluate the remission rate of microprolactinoma operated by endoscopic transphenoidal approachMethods: We retrospectively studied the surgical results of the 35 microprolactinomas operated between 2010 to 2017 in ...

Context: The immune checkpoint inhibitor (ICI) therapy is frequently used to treat advanced cancers. Autoimmune adverse events have been reported, such as endocrine side effects including frequent thyroid disorders and more rarely hypophysitis. The aim of this study was to describe retrospectively the association thyroiditis-hypophysitis.Patients and method: From 99 patients with endocrine side effects of the ImmuCare cohort, 18 patients with hypophysiti...

Objective: To collect clinical and treatment outcome data in a large patient cohort, and specifically to report experience with temozolomide (TMZ).Design: Cohort study based on an electronic survey open for participation to ESE members Dec 2015-Nov 2016.Results: Reports on 167 patients, 40 pituitary carcinomas, and 127 aggressive pituitary tumours were obtained. Median age at diagnosis was 43 (range 4–79) years. 59% of tumours...

TSH secreting pituitary adenomas are rare tumours for which the treatment of choice is neurosurgery but in some cases medical treatment with somatostatin analogs (SSA) can lead to a good control of symptoms and shrinkage of the tumour.The objective of this study was to review 30 patients diagnosed with TSH-omas between October 1981–July 2014, followed-up for a median of 43.93 months (1.12–192.11) in our University Hospital from Lyon, France.</p...

Context: Bilateral adrenalectomy (BADX) has become an important treatment option of Cushing’s syndrome (CS), especially when other treatments have failed. Long-term outcome is not well known.Objective: To evaluate long-term quality of life (QoL) of patients who underwent BADX for CS compared to other therapeutic options.Methods: Fourty five patients with all cause CS were identified: 23 patients had BADX and 22 underwent one o...

Introduction: Silent somatotroph tumours are GH immunoreactive (IR) pituitary tumours without clinical and biological signs of acromegaly. In our series, they represent 16% of all the somatotroph pituitary tumours. The aim of our study was to compare the somatotroph tumours with and without acromegaly to a better characterization of these silent tumours.Materials and methods: Fifty-nine tumours with acromegaly and 21 silent somatotroph tumours were studi...